Synergistic effect between curcumin (diferuloylmethane) and radiation on clonogenic cell death independent of p53 in prostate cancer cells

Journal of Cancer Science and Therapy

Volumn 2, Issue 6, 2010, Pages 171-181

  Nayak, Bijaya K ^a   Krishnegowda, Naveen K ^a   Galindo, Cynthia A ^a   Meltz, Martin L ^b   Swanson, Gregory P ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Clonogenic cell death; Curcuma longa; Curcumin; P53; Prostate cancer; Radiation; Synergy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CURCUMIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IONIZING RADIATION; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RIBONUCLEASE PROTECTION ASSAY; WESTERN BLOTTING;

EID: 78249272637     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000046     Document Type: Article

References (69)

1. Aggarwal BB (2008) Prostate cancer and curcumin: Add spice to your life. Cancer Biol Ther 7: 1436-1440.
2. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al. (2005) Curcumin suppresses the palcitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11: 7490-7498.
3. Ammon HP, Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57: 1-7.
4. An J, Chervin AS, Nie A, Ducoff HS, Huang Z (2007) Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 26: 652-661.
5. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB (2007) Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome C release: its suppression by ectopic expression of Bcl-2 and Bcl-xL. Carcinogenesis 23:143-150.
6. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, et al. (2010) Phase I escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8-14.
7. Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, et al. (2004) Apoptosismodulating agents in combination with radiotherapy - current status and outlook. Int J Radiat Oncol Biol Phys 58: 542-554.
8. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allredb DC (1993) P53 is mutated in a subset of advanced -stage prostate cancers. Cancer Res 53: 3369-3373.
9. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM (2004) Curcumin confers radiosensitizing effect in prostate cancer cell line PC3. Oncogene 23: 1599-1607.
10. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.
11. Chi SG, de Vere White RW, Meyers FJ, Siders DB, Lee F, et al. (1994) p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 86: 926-933.
12. Choi HY, Lim JE, Hong JH (2010) Curcumin interrupts the interaction between the androgen receptor and Wnt/ß-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis (Epub ahead of print).
13. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
14. Corson TW, Crews CM (2007) Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell 130: 769-774.
15. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, et al. (2003) Curcumin (Diferuloyl-methane) enhances tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2: 95-103.
16. Denis L, Morton MS, Griffiths K (1999) Diet and its preventive role in prostatic disease. Eur Urol 35: 377-387.
17. Dewey WC, Miller HH, Leeper DB (1971) Chromosomal aberrations and mortality of x-irradiated mammalian cells: emphasis on repair. Proc Natl Acad Sci USA 68: 667-671.
18. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al. (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499.
19. Don MJ, Chang YH, Chen KK, Ho LK, Chau YP (2001) Induction of CDK inhibitors (p21waf1 and p27kip1) and bak in the ß-lapachone apoptosis of human prostate cancer cells. Mol Pharmacol 59: 784-794.
20. Dorai T, Dutcher JP, Dempster DW, Wiernik PH (2004) Therapeutic potential of curcumin in prostate cancer-IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 60: 1-17.
21. Dorai T, Gehani N, Katz A (2000) Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 3: 84-93.
22. Downing SR, Russell PJ, Jackson P (2003) Alterations of p53 is common in early stage prostate cancer. Can J Urol 10: 1924-1933.
23. Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22: 9030-9040.
24. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, et al. (1999) Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 59: 5194-5201.
25. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, et al. (1997) P53 abnormalities in primary prostate cancer: single starnd conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The cooperative prostate network. J Natl Cancer Inst 89: 66-71.
26. Haupt S, Berger M, Goldberg Z, Haupt Y (2003) Apoptosis - the p53 network. J Cell Sci 116: 4077-4085.
27. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, et al. (1998) Nutrutional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 90: 1637-1647.
28. Herman JG, Stadelman HL, Roselli CE (2009) Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol 34: 1319-1327.
29. Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, et al. (2003) p53-independent induction of gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct1 and NF-Y. Oncogene 22: 7762-7773.
30. Hsing AW, Tsao L, Devesa SS (2000) International trends and patterns of prostate cancer incidence and and mortality. Int J Cancer 85: 60-67.
31. Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, et al. (2010) Thioredoxin Reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res 70: 1941-1950.
32. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60: 277-300.
33. Jutooru I, Chadalapaka G, Lei P, Safe S (2010) Inhibition of NF κB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 285: 25332-25344.
34. Kalkner KM, Wahlgren T, Ryberg M, Cohn-Cedermark G, Castellanos E, et al. (2007) Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncol 46: 909-917.
35. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, et al. (1999) Chemopreventive effect of curcumin, a naturally occurring anti-infl ammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59: 597-601.
36. Khafif A, Lev-Ari S, Vexler A, Barnea I, Starr A, et al. (2009) Curcumin: A potential radio-enhancer in head and neck cancer. Laryngoscope 119: 2019-2026.
37. Khan N, Adhami VM, Mukhtar H (2010) Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 17: R39-R52.
38. Khor TO, Keum Y-S, Lin W, Kim J-H, Hu R, et al. (2006) Combined inhibitory effects of curcumin and phenethyl Isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 66: 613-621.
39. Kim J-H, Xu C, Keum Y-S, Reddy B, Conney A, et al. (2006) Inhibition of EGFR signaling in human prostate cancer PC3 cells by combination treatment with b-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27: 475-482.
40. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, et al. (2008) Curcumin sensitizes human colorectal cancer xenografts in nude mice to γ-radiation by targeting nuclear factor-κB-regulated gene products. Clin Cancer Res 14: 2128-2136.
41. Lehman BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, et al. (2007) A dominant role for p53-dependant cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 6: 595-605.
42. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351: 453-456.
43. Li M, Zhang Z, Hill DL, Wang H, Zhang R (2007) Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by downregulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67: 1988-1996.
44. Lin L, Shi Q, Nyarko AK, Bestow KF, Wu CC, et al. (2006) Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anticancer agents. J Med Chem 49: 3963-3972.
45. Mu Z, Hachem P, Agrawal S, Pollack A (2004) Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol Biol Phys 58: 336-343.
46. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, et al. (2002) Curcumin-induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21: 8852-8861.
47. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB (2001) Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20: 7597-7609.
48. Nakamura K. Yasunaga Y, Segawa T, Ko D, Moul JW, et al. (2002) Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 21: 825-830.
49. Nayak BK, Das GM (2002) Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene 21:7226-7229.
50. Razoky C, Grignon DJ, Li Y, Gheiler E, Gururajanna B, et al. (1999) P53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. Pathol Res Pract 195: 129-135.
51. Ritter MA, Gilchrist KW, Voytovich M, Chappell RJ, Verhoven BM (2002) The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 53: 574-580.
52. Rosen EM, Fan SJ, Rockwell S, Goldberg ID (1999) The molecular and cellular basis of radiosensitivity: Implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest 17: 56-72.
53. Scott SL, Higdon R, Beckett L, Shi XB, de Vere White RW, et al. (2002) BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm 17: 647-656.
54. Shankar S, Srivastava RK (2007) Bax and Bak genes are essential for maximum apoptotic response by curcumin, a polyphenolic compound and cancer chemopreventive agent derived from turmeric, Curcuma longa. Carcinogenesis 28: 1277-1286.
55. Shankar S, Srivastava RK (2007) Involvement of Bcl-2 family members, phosphatidylinositol 3' kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 30: 905-918.
56. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854.
57. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al. (2001) Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7: 1894-1900.
58. Sheikh MS, Hollander MC, Fornance AJ Jr. (2000) Role of gadd45 in apoptosis. Biochem Pharmacol 59: 43-45.
59. Shishodia S, Chaturvedi MM, Aggarwal BB (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31: 243-305.
60. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, et al. (2008) Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8: 4521-4533.
61. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, et al. (1997) Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3: 1389-1397.
62. Swanson G (2006) Management of locally advanced prostate cancer: Past, present, future. J Urol 176: S34-S41.
63. Swanson GP, Faulkner J, Smalley SR, Noble MJ, Stephens RL, et al. (2006) Locally advanced prostate cancer treated with concomitant radiation and 5-fl uorouracil: Southwest oncology group study 9024. J Urol 176: 548-553.
64. Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph nodepositive prostate cancer. Cancer 106: 2531-2539.
65. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, et al. (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 296: 2329-2335.
66. Thompson IM, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, et al. (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177: 2106-2131.
67. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, et al. (2010) Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 3: 11.
68. Yu S, Shen G, Khor TO, Kim JH, Kong AT (2008) Curcumin inhibits Akt/ mammalian target of rapamycin signaling through protein phosphatasedependent mechanism. Mol Cancer Ther 7: 2609-2620
69. Zhang AL, Russell PL, Knittel T, Milross C (2007) Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. Prostate 67: 1630-1640.